Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

Launched by BELGIAN RESEARCH ON AIDS AND HIV CONSORTIUM · May 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well patients feel about using a long-acting injectable treatment called cabotegravir/rilpivirine (CAB/RPV) for managing HIV in Belgium. The study will gather information from people who have received this treatment and assess their experiences and satisfaction with it. Researchers will also collect data about the participants’ backgrounds and other health-related information.

To join this trial, participants must be adults aged 18 and older who have received at least one dose of the CAB/RPV treatment between September 2021 and March 2024. During the study, participants can expect to share their thoughts and feelings about the treatment, and their health outcomes will be monitored. This research aims to better understand the patient experience with this innovative treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.